Humalog Kwikpen U-100 (Insulin Lispro) — Medicare Part D spending
Eli Lilly & Co. · Rank #40 by total Part D spend · CMS data year 2023
Medicare Part D spent $1,208,385,334 on Humalog Kwikpen U-100 (Insulin Lispro) in 2023, the #40 drug by total Part D spending out of 3,598 drugs. That worked out to about $35.80 per dosage unit, $886 per claim and $2,888 per beneficiary, across 1,363,952 claims for 418,431 beneficiaries. Average spending per dosage unit rose +0.4% from 2022. These are aggregate Medicare program figures (gross drug cost), not the price you pay.
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
Humalog Kwikpen U-100 (Insulin Lispro) spending at a glance (2023)
| Metric | Humalog Kwikpen U-100 (Insulin Lispro) |
|---|---|
| Total Part D spending (2023) | $1,208,385,334 |
| Total spending (2022) | $1,100,404,540 |
| Year-over-year change in total spending | +9.8% |
| Average spending per dosage unit (2023) | $35.80 |
| Change in spend per dosage unit (YoY) | +0.4% |
| Avg annual change per dosage unit (2019-2023 CAGR) | +0.7% |
| Average spending per claim (2023) | $886 |
| Average spending per beneficiary (2023) | $2,888 |
| Total claims (2023) | 1,363,952 |
| Beneficiaries (2023) | 418,431 |
| Total dosage units (2023) | 33,756,807 |
| Manufacturer(s) | Eli Lilly & Co. |
| National rank by total spend (of 3,598 drugs) | #40 |
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
2022 vs 2023
| Metric | 2022 | 2023 | Change |
|---|---|---|---|
| Total spending | $1,100,404,540 | $1,208,385,334 | +9.8% |
| Avg spend per dosage unit | $35.65 | $35.80 | +0.4% |
| Avg spend per claim | $897 | $886 | — |
| Avg spend per beneficiary | $2,902 | $2,888 | — |
| Total claims | 1,226,763 | 1,363,952 | — |
| Beneficiaries | 379,168 | 418,431 | — |
How Humalog Kwikpen U-100 compares with nearby drugs
Drugs with total Part D spending closest to Humalog Kwikpen U-100 (Insulin Lispro):
| Drug (rank) | Total spend 2023 | Per dosage unit | Per-unit YoY |
|---|---|---|---|
| Humalog Kwikpen U-100 (Insulin Lispro) (this drug, #40) | $1,208,385,334 | $35.80 | +0.4% |
| Tagrisso (Osimertinib Mesylate) (#38) | $1,231,962,204 | $569.45 | +4.0% |
| Shingrix (Varicella-Zoster Ge/As01b/PF) (#39) | $1,211,171,028 | $212.26 | +8.4% |
| Skyrizi Pen (Risankizumab-Rzaa) (#41) | $1,189,321,833 | $20,593.60 | +8.1% |
| Austedo (Deutetrabenazine) (#42) | $1,123,439,045 | $103.61 | +6.5% |
| Cabometyx (Cabozantinib S-Malate) (#43) | $1,109,315,042 | $878.24 | +8.7% |
Frequently asked questions
How much does Medicare Part D spend on Humalog Kwikpen U-100?
Medicare Part D spent $1,208,385,334 on Humalog Kwikpen U-100 (Insulin Lispro) in 2023 (the latest CMS data year), across 1,363,952 claims for 418,431 beneficiaries. That ranks #40 of 3,598 drugs by total Part D spending. This is gross drug cost (Medicare, plan and beneficiary payments combined), not the price you personally pay.
What is the average spending per dosage unit for Humalog Kwikpen U-100?
In 2023, the weighted average Medicare Part D spending per dosage unit for Humalog Kwikpen U-100 (Insulin Lispro) was $35.80. Compared with 2022 it rose +0.4%. A "dosage unit" is one pill, tablet, milliliter or other billing unit, so this is not the price of a prescription.
Who makes Humalog Kwikpen U-100?
CMS attributes Humalog Kwikpen U-100 (Insulin Lispro) to Eli Lilly & Co. in the 2023 Part D spending file. Average spending per claim was $886 and per beneficiary $2,888.
Is the Humalog Kwikpen U-100 figure the price I pay?
No. These are aggregate Medicare Part D program figures (total gross drug cost and averages across all claims), published by CMS for transparency. Your out-of-pocket cost depends on your plan, formulary, deductible and coverage phase. Always check your plan and talk to your pharmacist or doctor.
Keep exploring
Source & what this means
Figures are from the CMS Medicare Part D Spending by Drug dataset (data year 2023, US public domain). "Total spending" is the gross drug cost — Medicare, plan and beneficiary payments combined — for Part D claims; it is not a list price, a negotiated price, or what any individual pays. Spending per dosage unit is volume-weighted across formulations. This is general public-spending information, not medical or pricing advice. Your own cost depends on your plan, deductible and coverage phase — verify with your Part D plan and a pharmacist. Data as of June 2026. See our methodology and disclaimer.
Last updated: 2026-06-20